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Abstract
Cerebral small vessel disease (CSVD) refers to a spectrum of clinical and 
neuroimaging findings resulting from pathological processes of various etiolo-
gies affecting cerebral arterioles, perforating arteries, capillaries, and venules. It 
is the commonest neurological problem that results in significant disability, but 
awareness of it remains poor. It affects over half of people over 65 years old and 
inflicts up to third of acute strokes, over 40% of dementia, and a significant decline 
in physical ability in otherwise asymptomatic, aging individuals. Moreover, the 
unifying theory for the pathomechanism of the disease remains elusive and hence 
the apparent ineffective therapeutic approaches. Given the growing literature for 
natural vitamin E (tocopherols and tocotrienols) as a potent antioxidant, this chap-
ter attempts to consolidate the contemporary evidence to shed plausible insights on 
the neuroprotective potentials of natural vitamin E in addressing the heterogenous 
CSVD spectrum, in health and in disease.
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1. Introduction
The recognition of vitamin E for its nutritive value was first linked to reproduc-
tive health in laboratory rats, then coined as factor X [1]. While alpha-tocopherol 
was the first vitamin E isomer to be recognized, there are now eight chemically 
distinct isomers known, consisting of alpha (α), beta (β), gamma (γ), and delta 
(δ)-isoforms of tocopherols and tocotrienols [2]. Current recommendations for 
adequate intake values are established based on α-tocopherol alone, whereas other 
forms of vitamin E need to meet other criteria [3]. Nature affords tocopherols in 
abundance, particularly in plants such as peanuts, sunflower seeds, and sesame 
seeds. The major dietary source of tocopherol is largely from corn and soybean oil 
consumption [4]. In contrast, the less ubiquitous tocotrienols are found in certain 
cereals and vegetables such as palm oil and annatto. A non-food source of tocotri-
enols is also recognized, namely, the latex of the rubber plant [2].
The well-established bioactivity of vitamin E is its antioxidant property by 
means of lipid peroxidation of cellular membranes [2]. As such, this property 
lends vitamin E the roles in promoting vascular health in arterial compliance 
studies and endothelial dysfunction biomarker. Pertinent to this, vitamin E 
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involvement is the vascular endothelium, which lines the intraluminal surface of 
blood vessels and is involved in the regulation of vascular tone, platelet activity, 
thrombosis, and the overriding pathogenesis of atherosclerosis [5, 6]. Vitamin E 
engages with the production of nitric oxide (NO) that relaxes the vascular smooth 
muscle while limiting free radicals to maintain arterial compliance [7]. More 
recently, vitamin E has been linked with anti-atherogenic effects that decrease 
low-density lipoprotein (LDL) oxidation and downstream inhibition of protein 
kinase C (PKC), adhesion molecules, monocyte transmigration, and vascular 
smooth muscle cell proliferation [8].
Therefore, the foregoing facts on vascular health and vitamin E profiles offer 
interrelated perspectives for a largely unexplored neurological condition termed 
cerebral small vessel diseases (CSVD). CSVD variable manifestations inflict small 
blood vessels or microcirculation at the subcortical and deeper parts of the brain. 
It has been widely reported to cause cerebral ischemic stroke or lacunar stroke that 
accounts for nearly a third of all stroke subtypes worldwide [9–12]. The pathologi-
cal consequences of small vessel disease on the brain parenchyma rather than the 
underlying diseases of the vessels is frequently viewed as the basis of CSVD [13]. 
Notably, CSVD lesions can be silent, and the affected individual may not have any 
apparent clinical symptoms. This silent (subclinical) lesion, with higher numbers 
(single or multiple), poses as a risk for vascular cognitive impairment, dementia, 
Alzheimer’s disease, and full-blown stroke [14, 15].
Furthermore, aging and chronic hypertension are known to accelerate CSVD, 
as the two conditions (physiological and pathological, respectively) may result in 
less efficient ability to self-regulate cerebral blood flow (cBF) from the concur-
rent varying systemic blood pressure levels and increased arterial stiffness which 
increases the speed and flow pulsatility in cerebral arterioles [16]. These hemo-
dynamic changes are postulated to cause variable degrees of endothelial damage 
in the blood-brain barrier (BBB) and alter its permeability through an increase of 
the shear stress [17]. Hence, the BBB breakdown is an important etiopathogenesis 
feature of CSVD [17–19].
In addition, there is an elevated production of reactive oxygen species (ROS) in 
CSVD that ultimately leads to endothelium dysfunctions [20, 21]. This is mainly 
due to the cumulative reactions and processes (i.e., high blood pressure, very low 
density of lipoproteins, diabetes mellitus, homocysteinemia, and smoking) that 
trigger and escalate the inflammatory responses and oxidative stress [20, 21]. This, 
in turn, heightens the release of adhesion molecules and recruits leukocytes, caus-
ing higher leukocyte-endothelial cell (EC) adhesion and reduced cBF. Accordingly, 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidases intensify the 
oxidative stress (a major source of ROS in vessel wall) and the consequent destruc-
tive impact on EC-dependent NO signaling [22, 23].
Collectively, this chapter focuses on highlighting the contemporary evidence on 
vitamin E, especially α-tocopherol and α-tocotrienol, their neuroprotective poten-
tial in relation to the heterogenous spectrum of CSVD manifestations, in promoting 
health as we age, and in mitigating disease.
2. Natural sources of vitamin E
2.1 Forms and structure
Vitamin E was first discovered in 1922 by Herbert Evans and Katherine Bishop at 
the University of California in Berkeley when they studied nutritive dependencies 
in reproduction [1]. They observed that rats fed with a purified diet of casein 18%, 
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cornstarch 54%, lard 15%, butterfat 9%, and salts 4% and adequate vitamin A (as 
cod liver oil), vitamin B (as yeast), and vitamin C (as orange juice) did not repro-
duce. They observed in females defective placental function, whereas the ovaries, 
ovulation, and implantation were unimpaired; and in males, there was a complete 
atrophy of the seminiferous epithelium [24, 25]. The addition of lettuce to the diet 
prevented embryo resorption during rodent gestation, and healthy pups were born 
again, thus, leading to the discovery of an anti-sterility factor, then termed as factor 
X. Wheat germ oil was later found to be a rich source of factor X. It was not until 
some 10 years later that Evans successfully isolated the components of vitamin E 
family and named them tocopherols (Greek: toc (child), phero (to bring forth), and 
–ol because it behaves chemically like an alcohol) [25, 26].
Meanwhile, tocotrienol was named by Bunyan and colleagues, when they 
identified the unsaturated derivatives of tocols, isolated from the latex of the rubber 
plant (Hevea brasiliensis) [27]. The structure of tocotrienols was further described 
by Pennock and colleagues, who found that palm oil was a rich source of this “new 
tocopherol” [28]. Palm oil derived from Elaeis guineensis (African oil palm) now 
represents the richest source of the lesser characterized vitamin E, α-tocotrienol.
α-Tocopherol is currently the only form of vitamin E recognized to meet human 
requirements, and recommended adequate intake values are established based 
on α-tocopherol alone. Other forms of vitamin E must fulfill the following to be 
recognized as vitamin E: (1) converted to α-tocopherol in humans and (2) recog-
nized by the α-tocopherol transfer protein. Plasma α-tocopherol concentrations 
in humans range from 11 to 37 μmol/L, whereas γ-tocopherol concentrations are 
roughly 2–5 μmol/L, and tocotrienol concentrations are less than 1 μmol/L in non-
supplemented humans [3].
Tocopherols are widely found in nature, predominantly in plant seeds such as 
peanuts, sunflower seeds, almonds, walnuts, and sesame seeds. The major dietary 
source of tocopherol comes from the widespread use of corn and soybean oil [4]. 
Tocotrienols, which are less ubiquitous, are found in certain cereals and vegetables 
such as palm oil, rice bran oil, and annatto. Lower levels of tocotrienols can be 
found in grapefruit seed oil, oats, hazelnuts, maize, olive oil, buckthorn berry, rye, 
flaxseed oil, poppy seed oil, and sunflower oil [3]. A non-food source of tocotri-
enols is the latex of the rubber plant. While it has been shown that the different 
vitamin E forms are interconvertible by plants, there has been no convincing 
evidence that the same is true for animals [29].
While alpha-tocopherol was the first vitamin E isomer to be recognized, there 
are now eight chemically distinct isomers known, consisting of alpha (α), beta (β), 
gamma (γ), and delta (δ)-isoforms of tocopherols and tocotrienols [2], as shown in 
Figure 1. The molecular structure of vitamin E is based on a chromanol ring with a 
side chain at the C2 position. While the lipophilic tail of tocopherols is completely 
saturated, tocotrienols have three double bonds, at the 3′, 7′, and 11′ positions. 
Plants synthesize eight different forms of vitamin E, tocopherols and tocotrienols, 
which include α, β, γ, and δ forms that differ in the number of methyl groups on the 
chromanol ring [29]. The slight difference in structure between isoforms translates 
into striking variations in activity. Compared with tocopherols, tocotrienols are 
more efficiently incorporated into membranes and cultured cells [30], thus giving 
rise to more potent antioxidant activities.
2.2 Mechanism and regulation of metabolism
Upon oral administration, vitamin E, a lipid-soluble vitamin, requires biliary 
and pancreatic secretions in order to form micelles for the subsequent uptake by 
intestinal epithelial cells [3]. Therefore, the absorption of vitamin E is enhanced if 
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taken with food which contributes fat, thereby triggering the secretion of enzymes 
that facilitate the formation of micelles required for absorption. Despite many 
years since its discovery, there is still a lack of understanding of the mechanism of 
absorption, liver trafficking, and disposition of vitamin E isoforms [31].
The general understanding of vitamin E absorption and trafficking is that 
orally administered vitamin E undergoes intestinal luminal processing, where it 
accumulates in lipid droplets, which then coalesce with nascent chylomicrons [32]. 
The vitamin E isoforms are not discriminated during the intestinal absorption or 
incorporation into chylomicrons. Chylomicrons then transport vitamin E from the 
intestine through circulation to the liver, which metabolizes or resecretes vitamin E 
back into the plasma for trafficking to tissues via enriched lipoproteins.
After the liver takes up chylomicron remnants, vitamin E isoforms with greater 
affinity to α-tocopherol transport protein (αTTP) are preferentially bound for 
transport to tissues, thereby avoiding catabolism. αTTP expressed in the liver is 
required to facilitate vitamin E transport from the liver to other tissues and organs. 
The discrimination of vitamin E isoforms occurs in the liver as a result of differing 
affinity of isoforms to αTTP. αTTP has the ability to bind to both α-tocotrienol and 
α-tocopherol, but αTTP binds to α-tocotrienol with approximately 10 fold lower 
affinity than that for α-tocopherol [33]. All lipoproteins are involved in the traffick-
ing of α-tocopherol to the tissues, although very low-density lipoprotein apparently 
leaves the liver preferentially enriched in α-tocopherol compared with LDL or 
high-density lipoprotein (HDL) [29]. Discrimination between dietary forms of 
vitamin E is dependent upon the hepatic αTTP to maintain circulating α-tocopherol 
[34]. α-tocopherol is also most retained in tissues due to preferential binding by 
αTT, facilitating secretion into plasma [2] and trafficking to tissues, whereas large 
portions of other forms of vitamin E are catabolized through general xenobiotic 
processes [4].
Interestingly, a study using αTTP knockout mice showed that orally admin-
istered α-tocotrienol was absorbed and delivered to vital organs, despite being 
deficient of αTTP [35]. In organs such as adipose tissue, skin, skeletal muscle, 
and the heart, α-tocotrienol levels were many folds higher than α-tocopherol in 
supplemented αTTP knockout mice. Oral supplementation of the female mice with 
α-tocotrienol also restored fertility, suggesting that it can be successfully delivered 
to the relevant tissues and that α-tocotrienol supported reproductive function under 
Figure 1. 
Chemical structures of (A) tocopherol and (B) tocotrienol. Note the three double bonds in the tocotrienol 
side chain. Note: Isoforms—α (R′ = CH3, R″ = CH3); β (R′ = CH3, R″ = H); γ (R′ = H, R″ = CH3); δ (R′ = H, 
R″ = H).
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conditions of α-tocopherol deficiency. These findings suggest TTP-independent 
mechanisms for the tissue delivery of oral α-tocotrienol. While αTTP may contrib-
ute to tocotrienol trafficking, αTTP does not represent a major or sole mechanism of 
α-tocotrienol transport in the body [35].
Vitamin E is metabolized by ω-hydroxylation by cytochrome P450 (CYP), 
followed by β-oxidation and conjugation to generate carboxychromanols and 
conjugated counterparts [2, 29]. The tail of vitamin E isoforms is ω-hydroxylated by 
CYP 4F2 and subjected to several rounds of β-oxidation, which ultimately results in 
the formation of carboxyethyl hydroxy chromanol (CEHC) (Figure 2). Thus, the 
tail-shortened, water-soluble metabolite, CEHC, is synthesized and excreted in the 
urine [36]. Conjugation such as sulfation and glucuronidation of the phenolic on 
the chromanol may also take place in parallel with β-oxidation when there is a high 
intake of vitamin E forms [4]. Although α-tocopherol largely escapes catabolism 
and ends up in the blood circulation, α-CEHC is synthesized endogenously when 
the quantity of hepatic α-tocopherol exceeds the capacity of αTTP to facilitate 
α-tocopherol secretion from the liver into the circulation [31].
Traber and colleagues established that urinary α-CEHC might be useful to 
noninvasively assess α-tocopherol adequacy, especially in populations with meta-
bolic syndrome-associated hepatic dysfunction that likely impairs α-tocopherol 
trafficking. Their finding also suggests that people with metabolic syndrome may 
have a higher requirement for vitamin E due to poorer trafficking leading to lower 
apparent α-tocopherol bioavailability. However, it is still unknown whether urinary 
α-CEHC excretion reflects α-tocopherol intake from a single meal or whether its 
changes reflect long-term vitamin E status [31].
Recently, Traber and colleagues, which lead as one of the most prolific 
research groups in vitamin E tocopherol, suggested novel approaches to assess 
α-tocopherol absorption and trafficking in order to establish human vitamin 
E requirements [32]. Their study observed that the absorption of α-tocopherol 
is not necessarily limited by the absence of fat or fasting and that the absorp-
tion is highly dependent on chylomicron assembly processes. The transport 
of α-tocopherol across the intestines may be prolonged during fasting and 
Figure 2. 
Tocol structures. The chromanol head group is identical in the alpha-forms of synthetic (A) all-racemic 
α-tocopherol [2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl) chroman-6-ol], (B) natural (RRR) 
α-tocopherols [(R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl) chroman-6-ol], (C) 
α-tocotrienol [2,5,7,8-tetramethyl-2-((3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl) chroman-6-ol], and 
(D) the metabolite of all three isoforms, α-carboxyethyl hydroxychromanol (CEHC) [3-(6-hydroxy-2,5,7,8-
tetramethylchroman-2-yl) propanoic acid]. CEHC results from the ω-hydroxylation, followed by β-oxidation 
of the side chain (as well as conjugation with glucuronide, sulfate, or other compounds), yielding a  
water-soluble molecule that is largely excreted in urine [34].
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potentiated by eating. However, the authors recognized the conclusion derived 
from the study has several limitations, including small sample size, lack of 
randomization or blinding, and compliance issues, leading to an imbalance with 
attendant potential for baseline and residual confounding. Nevertheless, if proven 
in a larger trial, this observation changes the conventional thinking that vitamin E 
needs to be taken with or immediately after meal to enhance absorption and also 
reflects that there is still much to learn on the absorption and transport of vitamin 
E in humans.
2.3 Antioxidant activities
The most established bioactivity of vitamin E is its antioxidant property, 
primarily against lipid peroxidation in biological membranes [2]. By quenching 
the lipid radicals, vitamin E, as chain-breaking antioxidant, terminates the chain 
reaction of the oxidation of polyunsaturated fatty acids (PUFAs) [3]. This function 
is critical to ensure the integrity of cellular membranes and systems which rely on 
the abundance of PUFAs, such as the nervous system. Hence, neurological symp-
toms such as progressive ataxia and hyporeflexia are manifestations of vitamin E 
deficiency as a result of malabsorption.
Tocopherols and tocotrienols are potent antioxidants that scavenge lipid peroxyl 
radicals by donating hydrogen from the phenolic group on the chromanol ring 
[4]. A synergistic antioxidant system made up of vitamin C and other hydrogen 
donors such as thiol antioxidants, namely, glutathione and lipoic acid, reacts with 
the resulting tocotrienoxyl or tocopheroxyl radicals to regenerate vitamin E [37], 
returning it to its reduced state for further use (Figure 3). There is very little 
evidence in vivo for more advanced vitamin E oxidation products [34].
Packer and colleagues noted that the substituents on the chromanol nucleus and 
properties of side chain (saturated vs. unsaturated) were critical to the effectiveness 
of the different vitamin E homologs [37]. Preferential distribution of α-tocopherol 
to the tissues in vivo may have contributed to its greater impact compared 
with other homologs, but the structural differences between α-tocopherol and 
α-tocotrienol have given rise to differences in reactivity observed in in vitro and 
in vivo studies.
Figure 3. 
The antioxidant network showing the interaction among vitamin E, vitamin C, and thiol redox cycles 
[37]. Notes: *thiol transferase (glutaredoxin), protein disulfide isomerase, glutathione (GSH)-dependent 
dehydroascorbate reductase, thioredoxin (TRX) reductase.
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Tocotrienols were suggested to be more effective scavengers of peroxyl radicals 
due to more even distribution in the phospholipid bilayer, more effective interac-
tion with lipid peroxyl radicals [4], stronger disordering of membrane lipids, and 
greater recycling of chromanoxyl radical due to closer location to the membrane 
surface [37]. The chromanoxyl radical of α-tocotrienol was found to be recycled in 
membranes and lipoproteins more quickly than the corresponding α-tocopheroxyl 
radical [38].
The antioxidant activity of vitamin E is critical to a healthy nervous system, as 
evident from the consequences of neurological function under deficient condi-
tion. The vitamin E protection of PUFAs leads to neuroprotective effects under 
pathologic and high oxidative stress conditions. Due to the early discovery of 
α-tocopherol as an essential vitamer and its ubiquitous nature, most research in 
vitamin E, concerning the mechanisms of action and physiological implications of 
deficiency, has centered on tocopherols. Tocotrienols, without having any appar-
ent consequence of deficiency and being not inherently detectable in non-supple-
mented humans or animals, were not the focus of vitamin E-related research until 
much later. Since the discovery of rich sources of tocotrienols and subsequent 
availability as an active ingredient, there is growing evidence that tocotrienols 
have superior potency in terms of antioxidant activity and modulation of impaired 
biochemical pathways resulting in physiologically beneficial effects.
Arachidonic acid (AA), one of the most abundant PUFAs of the central nervous 
system, is highly susceptible to oxidative metabolism under pathologic conditions. 
[39]. A number of neurodegenerative conditions in the human brain are associated 
with disturbed PUFA metabolism of AA, including acute ischemic stroke [40]. 
Cleaved from the membrane phospholipid bilayer by cytosolic phospholipase A2 
(cPLA2), AA is metabolized by both enzymatic and nonenzymatic pathways into 
neurotoxic metabolites. Palm oil-derived α-tocotrienol at nanomolar concentrations 
has been shown to attenuate both enzymatic and nonenzymatic mediators of AA 
metabolism and neurodegeneration [39] (Figure 4).
Figure 4. 
The arachidonic acid (AA) cascade and potential target sites for α-tocopherols (αTOC) and α-tocotrienols 
(αTCT) [39]. cPLA2, cytosolic phospholipase A2; 12-LOX, 12-lipoxygenase; c-Src, proto-oncogene tyrosine-
protein kinase or simply c-Src (cellular sarcoma); 12-HPETE, 12-hydroperoxyeicosatetraenoic acid; COX, 
cyclooxygenase.
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2.4 Benefits in vascular health
Vitamin E has also been associated with improved vascular health in studies 
measuring arterial compliance and endothelial dysfunction as biomarkers. Vascular 
endothelium, which lines the blood luminal surface of vessels, is involved in the 
regulation of vascular tone, platelet activity, and thrombosis and intimately involved 
in the pathogenesis of atherosclerosis [5, 6]. The endothelium is an integral part 
of the vasculature and is involved in promoting an atheroprotective environment 
via the complementary actions of endothelial cell-derived vasoactive factors [41]. 
Vasomotor tone is modulated through the release of endothelium-derived relaxing 
factors (EDRFs) such as NO [6]. Impaired vascular homeostasis can lead to endothe-
lial dysfunction, which contributes to atherosclerosis [41]. Intact endothelium is also 
needed for normal arterial compliance, a predictor of cardiovascular events. Arterial 
compliance, which can be assessed by pulse wave velocity (PWV) and augmentation 
index (AI), can be improved in healthy subjects even with dietary interventions [7].
In a randomized controlled trial, subjects with the following risk factors, hyper-
cholesterolemia (13 subjects), smokers (14 subjects), or both (15 subjects), were 
supplemented with placebo or vitamin E for 4 months. The authors hypothesized 
that long-term supplementation with vitamin E would improve endothelium-
dependent relaxation in hypercholesterolemic patients and/or chronic smoking, two 
risk factors that have been associated with increased radical formation, impaired 
endothelial vasodilator function, and increased plasma levels of autoantibodies 
against oxidized LDL [6]. The study found the most severe endothelial vasodila-
tor dysfunction in patients with both risk factors present. Vitamin E significantly 
improved endothelium-dependent relaxation in forearm resistance vessels of hyper-
cholesterolemic smokers. There was a significant relationship between improve-
ment in acetylcholine-induced vasodilation and the change in autoantibody titer 
against oxidized LDL (r = −0.59; p = 0.002) [6].
Moreover, in a randomized controlled trial, 36 healthy male volunteers were 
supplemented with placebo or tocotrienol-rich vitamin (50, 100, 200 mg/day) 
with self-emulsifying formula for 2 months [7]. Arterial compliance was assessed 
using carotid-femoral PWV and AI, at baseline and after 2 months of supplementa-
tion. Subjects treated with tocotrienols at doses of 100 and 200 mg/day showed 
significant improvement in arterial compliance with PWV reductions of 0.77 m/s 
(p = 0.007) and 0.65 m/s (p = 0.002), respectively. The placebo group did not show 
a reduction in PWV and AI compared with baseline. The treatment had no effect on 
blood pressure, serum total cholesterol, and LDL-C [7], which are potential con-
founding factors to the observed improvement in arterial compliance. The improve-
ment in vascular function can be achieved through mechanisms involving enhanced 
NO production by the endothelium and inhibition of free radicals that inactivate 
EDRF. Vitamin E can potentially increase the production of NO, which relaxes the 
vascular smooth muscle cells, while also neutralizing free radicals which preserve 
the action of EDRF to maintain arterial compliance [7].
In addition to promoting vascular health, vitamin E is also postulated to exert 
anti-atherogenic effects via its ability to decrease LDL oxidation, quench free radi-
cals, inhibit protein kinase C (PKC), inhibit expression of adhesion molecules and 
monocyte transmigration, and impair vascular smooth muscle cell proliferation [8].
3. Cerebral small vessel disease
The general ischemia implicated in CSVD of small blood vessels (i.e., arterial 
tree occlusion in particular) involving the subcortical and deeper parts of the brain 
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has been widely reported to cause cerebral ischemic stroke or lacunar stroke and 
accounts for nearly 30% of all stroke subtypes worldwide [9–12].
3.1 Characteristic and classification
The complexity and overlapping pathophysiological mechanism of the disease 
make the interpretation of CSVD debatable. However, it is a widely accepted view 
that pathological consequences of small vessel disease (SVD) on the brain paren-
chyma rather than the underlying diseases of the vessels serve as the basis of CSVD 
[13]. Hence, the injury in the brain parenchyma that is linked with leptomeningeal 
and intracerebral vessel pathology that vascularizes with poor collaterals in the 
deep white matter and subcortical gray matter is the main diagnostic landmark of 
CSVD. Moreover, CSVD is generally due to several vasculo-pathological processes 
that affect and cause occlusion to the small perforating cerebral arterioles, capillar-
ies, and venules (of sizes 50–400 mm), which are small arteries (chiefly of middle 
cerebral artery tributaries) that penetrate and supply the brain subcortical region, 
resulting in various lesions in the brain [42–46].
Several manifestations of CSVD can be seen through clinical, radiological 
(i.e., neuroimaging such as CT or MRI), or pathological phenomena with various 
etiologies [46–49]. Recent advancement in neuroimaging techniques had enabled 
the imaging-based (such as MRI) identification and characterization of multiple 
manifestation of CSVD including white matter hyperintensities (WMHs) of 
presumed vascular origin or leukoaraiosis, lacunes of presumed vascular origin 
(i.e., small subcortical infarcts and silent brain infarcts, SBI), perivascular spaces, 
microinfarcts, and cerebral microbleeds (CMBs) [46, 50, 51]. Alarmingly, the 
aforementioned lesions can be silent, and the affected individual may not have 
any clinical symptoms. More importantly, this silent lesion with higher number 
of single or multiple, is associated with higher risk of mild cognitive impairment, 
dementia, Alzheimer’s disease, and full-blown stroke [14, 15].
There are several etiopathogenic classifications of CSVD. However, the most 
prevalent forms of CSVD are amyloidal CSVD (sporadic and hereditary cerebral 
amyloid angiopathy [CAA]) and non-amyloidal CSVD (arteriolosclerosis, age-
related, vascular risk-factor-related SVD, i.e., microatheroma, lipohyalinosis, 
fibrinoid necrosis, and segmental arterial disorganization) [42, 52, 53]. Other less 
common forms of CSVD include inherited or genetic CSVD that is recognizably 
different from CAA (i.e., Fabry’s disease and cerebral autosomal dominant arteri-
opathy with subcortical ischemic strokes and leukoencephalopathy [CADASIL]), 
inflammatory and immunologically mediated CSVD (i.e., rheumatoid vasculitis, 
lupus erythematosus, and CNS vasculitis secondary to infection), venous col-
lagenosis, and other CSVD (i.e., non-amyloid microvessel degeneration in AD and 
postradiation angiopathy) [42, 52, 53].
3.2 Neuroepidemiology and health burden
Different manifestations of CSVD based on neuroimaging findings result in 
different and overlapping health burden and epidemiology [54]. Increasing age has 
been reported to elevate the finding of WMHs, lacunes, perivascular spaces, and 
CMBs in healthy populations [54–56]. However, increased vascular risk factors are 
consistent with the prevalence of CMBs but not in other imaging findings [56, 57]. 
Race, ethnicity, and gender with adjusted age also explain the variability of these 
imaging findings, whereby some findings had reported that higher WMH grade and 
volume were found in ethnic or racial minorities than non-Hispanic white [58] and 
WMHs were much higher in women than men, although no definite mechanism 
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was reported for this gender difference [59]. In addition, previous study had 
reported stroke-free elderly Hispanic and/or Latino had SBI (16%), especially in 
subcortical region (82.9%) [60] and perivascular spaces (48%) [61].
In other ethnic groups, previous study had reported that the prevalence of 
WMHs in South Asians and Europeans is similar, although South Asian elderly 
individuals with known vascular risk are more likely to be associated with higher 
WMHs [62]. Meanwhile, data in three Asian countries (Singapore, Hong Kong, and 
Korea) have shown that elderly Asians with higher SVD burden are associated with 
cognitive decline [63]. This was further supported by the Taizhou Imaging Study, 
whereby the authors found increased incidental findings of WMHs (10.68%), 
lacunes (26.69%), CMBs (18.51%), and perivascular spaces (27.76%) in elderly 
Chinese with vascular risk [64]. However in the Japanese population, most are 
having moderate to mild dilated perivascular spaces, especially in the centrum 
semiovale and basal ganglia [65]. Thus, it is apparent that more data are required to 
understand the role of racial and/or ethnic contributions for the presence of differ-
ent CSVD manifestations.
The effects of several manifestations of CSVD on cognition seem to be invariably 
influenced by the location of the lesion(s). The damaged and reduced white matter 
integrity in the frontal lobe and its dysfunction are associated with reduced transmis-
sion of information to other parts of the brain in the presence of WMHs [54], lacunes 
(deep nuclear [78.2%], posterior fossa [10.1%]) [66], and perivascular spaces [65, 
67]. In contrast, temporal lobe lesion is more associated with the findings of lobar and 
deep CMBs [68, 69]. Several studies have reported that an increase in WMHs is asso-
ciated with worse general and specific domain of cognitive performance, especially 
in executive function, processing speed, and episodic memory [70–73]. Intriguingly, 
an increase in WMHs with reduced cognitive performance is similar to the individual 
with amyloid load, mild parkinsonism, and functional impairments [70].
Furthermore, reduced cognitive ability has been reported in elderly and non-
demented people with the presence of lacunes of presumed vascular origin [54, 72, 
74]. Memory declines have also been associated with thalamic infarcts, whereas 
decreased psychomotor speed is associated with non-thalamic infarcts [75]. In 
contrast, the presence of a lesion in the perivascular spaces reduces the individual 
processing speed [76] and, in others, reported no effect on the cognitive perfor-
mance [67]. Meanwhile, a decrease in global cognitive performance and domain 
specific has been linked with the location of CMBs [77].
3.3 Pathomechanism
Despite the growing insights from histopathological, epidemiological, and 
physiological studies in the past two decades, the underlying pathomechanism of 
CSVD remains contentious [46, 53]. In general, it is recognized that advanced age 
and the presence of chronic hypertension may reduce the ability to self-regulate 
cBF in response to various systemic blood pressure levels and increased arterial 
stiffness, hence the increased speed and flow pulsatility in cerebral arterioles [16]. 
These hemodynamic changes are postulated to inflict a certain degree of endothe-
lial damage in the BBB and alter its permeability through an increase of the shear 
stress [17]. Hence, the BBB breakdown is an important etiopathogenesis feature of 
CSVD [17–19].
Another key factor thought to contribute to the pathogenesis of CSVD is endo-
thelial dysfunction, with elevated biomarkers as the surrogates [78, 79]. The endo-
thelial dysfunction involvement is also associated with metabolic syndrome [80, 81] 
and hence a strong link with CSVD. Furthermore, this dysfunction is also implicated 
for a higher risk of aging-related disease [82, 83]. In addition to the endothelium, 
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cross-talk among cellular components of the BBB, such as pericytes, astrocytes, and 
oligodendrocyte precursor cells (OPCs), may be involved in the microvascular dam-
age as precursors for the onset and progression of CSVD [84, 85]. In relation to this, 
reduced white matter integrity due to changes in oligodendrocytes has been shown 
in CSVD, whereby the EC-OPC signaling became compromised and altered the ECs’ 
ability to secrete the releasing factor crucial for the growth and survival of OPCs to 
eventually cause oligodendrocytes prone to damage [86]. Therefore, the interaction 
of multiple BBB components may play a crucial role in the discovery and develop-
ment of new prevention steps and therapies for CSVD.
In parallel, an increased activity of matrix metalloproteinase-2 (MPP2) from 
endothelial cell membrane (ECM) also caused tight junctions (TJs) to dissemble. 
TJ damage eventually leads to basement membrane degradation and endothelial 
damage and, hence, endothelial dysfunction. This results in BBB damage, making 
it vulnerable to the infiltration of neutrophils, monocytes, and blood components 
into the ECM [53]. Activated neutrophils induce the activation of ROS, proteolytic 
enzymes, and cytokines, thus causing higher leukocyte-EC adhesion and reduced 
cBF (Figure 5). Meanwhile, activated monocytes will be induced by cytokine and 
neopterin to cause inflammation in the ECs. Cumulatively, the increased shear and 
oxidative stress from the system also lead to the activation of blood components 
and increased production of microparticles, reduced tissue factor pathway inhibi-
tor, and increased fibrinogen accumulation that result in lumen narrowing and 
consequent cBF reduction [53].
Understandably, the role of hypoperfusion or reduced cBF in endothelial dys-
function for CSVD has been hypothesized [87]. Generally, the regulation of cBF is 
mediated by NO signaling; thus, NO serves as a marker for endothelial dysfunction 
[88]. Since endothelial dysfunction is associated with increased BBB permeability, 
this would worsen brain parenchyma and white matter lesions given the reduced 
integrity of ECs [89]. In addition, the increased expression of the mutated NOTCH3 
gene (a genetic determinant of CADASIL) in pericytes was found to contribute 
to CSVD pathogenesis due to abnormal cross-talk between ECs and pericytes 
[87]. Therefore, one can posit that increased BBB permeability, reduced cBF, and 
impaired cerebral autoregulation serve as three main interrelated underlying patho-
genesis precursors to the development and progression of CSVD, notwithstanding 
the role of other potential and novel factors.
3.4 Role of reactive oxygen species
Multiple studies have reported that the early detection of cognitive and motor 
decline in neurodegenerative disease has been linked with protein, lipids, sugar, and 
nucleic acid oxidation [90, 91]. Therefore, it can be postulated that changes or dam-
age to the cerebral vasculature, BBB, and cBF is due to localized oxidative stress, 
hence initiating the neurodegenerative changes in the brain tissue.
Generally, overproduction of oxidants by NADPH oxidases and malfunction 
or reduced activities of antioxidant enzymes may result in oxidative stress [52]. 
The imbalance between antioxidants and prooxidants in aging and age-related 
neurological disease is regarded to be mainly due to ROS [92] which is a large group 
of oxygen radicals (i.e., superoxide anion radical, hydroxyl radical, peroxyl radical, 
and alkoxyl radical) and non-radicals (i.e., hydrogen peroxide, organic hydroper-
oxide, singlet molecular oxygen, electronically excited carbonyls, and ozone) [52, 
64]. NADPH oxidase- and superoxide dismutase-mediated enzymatic conversion 
of molecular oxygen to superoxide initiates the production of ROS; however, the 
production of ROS can also be mediated by spontaneous transformation of non-
radical hydrogen peroxide [93].
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There are multiple oxidative markers used to correlate with neurodegenera-
tive disease including CSVD, for example, thioredoxins (positively correlate with 
severity of acute ischemic stroke and infarct volume) [94], thioredoxin reductase 
Figure 5. 
General pathomechanism and role of ROS in CSVD. ECs, endothelial cells; BBB, blood–brain barrier; ECM, 
extracellular matrix; cBF, cerebral blood flow; NO, nitric oxide; eNOS, endothelial nitric oxide synthase; ROS, 
reactive oxygen species; RNS, reactive nitrogen species; COX, cyclooxygenase; NADPH, nicotinamide adenine 
dinucleotide phosphate; MPs, microparticles; TNF-alpha, tumor necrosis factor-alpha; WMHs, white matter 
hyperintensities; CMBs, cerebral microbleeds; AD, Alzheimer’s disease.
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(reduced thioredoxin reductase attenuates the capacity of endothelium-dependent 
vasodilatory) [95], and peroxiredoxins (higher during stroke onset and traumatic 
brain injury) [96]. Moreover, reduced plasma levels of uric acid and vitamins E, A, 
and C have been used as antioxidant biomarkers for Alzheimer’s disease and also 
Parkinson’s disease [97–100]. Similarly, coenzyme Q10 (i.e., ubiquinone Q10) is 
another antioxidant that has been shown to provide potential protective effects for a 
spectrum of CSVD and cerebral metabolic syndrome [82].
In CSVD, the elevated production of ROS is mainly due to reactions and 
process (i.e., high blood pressure, very low density of lipoproteins, diabetes, and 
homocysteinemia and smoking) that lead to inflammatory mechanism and oxida-
tive stress hence causing endothelium dysfunction [20, 21]. Induction of oxidative 
stress further enhanced the releasing of adhesion molecules and recruiting of 
leukocytes causing higher leukocyte-EC adhesion and reduced cBF (Figure 5). 
NADPH oxidases induce oxidative stress (major source of ROS in vessel wall), and 
its destructive impact on EC-dependent NO signaling has been widely studied 
[22, 23]. The NADPH oxidases can be stimulated by mechanical forces and vaso-
active agonists (i.e., thrombin, platelet-derived growth factor, and tumor necrosis 
factor-alpha) hence enhancing the production of ROS through superoxide anion 
radical synthesis [101–103].
Another two key enzymes that facilitate the production of ROS include cycloox-
ygenase (COX) and enzymatic cascade in mitochondria (i.e., oxidative phosphory-
lation). COX is an important enzyme that produces superoxide in cerebral blood 
vessels through prostaglandin H2 synthesis mediated by AA [104, 105]. Superoxide 
can also be synthesized after endothelial nitric oxide synthase dysfunction that 
halts the NO production. This eventually reduces the bioavailability of NO and, in 
turn, facilitates the production of reactive nitrogen species (RNS) to cause reduced 
anti-inflammatory, reduced vasodilating, increased platelet aggregation, disinhibi-
tion of leukocyte adhesion, and reduced antiproliferative effects of NO [52, 106]. 
Hence, biomarkers of oxidative stress can be used to study the redox imbalance in 
individuals with WMHs while it draws a plausible therapeutic avenue with targeted 
dietary supplements to reduced ROS and RNS that would be neuroprotective 
against CSVD onset and/or manifestations [107].
4. Prospects of vitamin E for CSVD neuroprotection
As remarked in the previous sections, increasing body of evidence indicated 
that oxidative stress might play a pivotal role in the largely elusive pathomecha-
nism of CSVD and other neurodegenerative disease, including cognitive 
impairment. Moreover, targeting oxidative stress, as a therapeutic approach of vas-
cular-related disease, has been an area of continuing interest given its significance 
on the aging world population and the rising trend of noncommunicable disease 
burden, typically cardio-cerebrovascular disorders which include CSVD. However, 
informative and converging data on vitamin E and its neuroprotective potential for 
CSVD are scarce.
Central to this proposition of vitamin E potential in CSVD is the involvement 
of ROS in the physiological role for normal regulation of cerebral vascular event. 
Hence, a balance between mitigating oxidative stress and normal physiological role 
should be considered in this ROS-centric approach for natural vitamin E in CSVD 
neuroprotective potentials. Nonetheless, the idea of attaining or sustaining certain 
levels of antioxidants to mitigate vascular oxidative stress remains a contentious 
issue. For instance, antioxidants such as vitamin E have been proven beneficial for 
vascular function in small clinical and experimental trials [108], whereby vitamin 
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E supplementation had been shown to reduce the onset of WMHs in small clinical 
trials [109]. Moreover, natural vitamin E also had been shown favorable to lessen 
cognitive impairments in CSVD animal models [110, 111]. Notwithstanding, a 
Figure 6. 
Putative neuroprotective potentials of natural vitamin E in targeting ROS in CSVD manifestations. αTCT, 
α-tocotrienols; αTOC, α-tocopherols; ECs, endothelial cells; BBB, blood–brain barrier; ECM, extracellular 
matrix; cBF, cerebral blood flow; NO, nitric oxide; eNOS, endothelial nitric oxide synthase; ROS, reactive 
oxygen species; RNS, reactive nitrogen species; COX, cyclooxygenase; NADPH, nicotinamide adenine 
dinucleotide phosphate; MPs, microparticles; TNF-alpha, tumor necrosis factor-alpha; WMHs, white matter 
hyperintensities; CMBs, cerebral microbleeds; AD, Alzheimer’s disease.
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larger-scale clinical trial had shown less convincing beneficial outcomes on stroke 
and vascular disease prevention with antioxidant (i.e., vitamin E) supplementa-
tion [112].
Moreover, utilizing other antioxidants such as coenzyme Q10 has been reported 
to have potential neuroprotective effects in treating oxidative stress-induced 
metabolic syndrome with CSVD-related deterioration with reduced plasma level 
of coenzyme Q10 in experimental animal model with metabolic syndrome [82]. 
Nonetheless, recent studies on oxidative stress-induced diet reported weak or 
no apparent association in modifying the cardiovascular risk in an animal model 
(normotensive wild-type mice, C57BL/6 J), at least in its impact on systemic blood 
pressure [113].
The inconsistency in the reports of the potential neuroprotective effects of anti-
oxidant (natural vitamin E) in cerebrovascular disease is partly due to the apparent 
lack of optimization in terms of concentrations/doses of the vitamin E used. This 
is despite the supportive data on supra(optimal)-physiological concentration of 
vitamin E (especially α-tocotrienol) that can interrupt the superoxide and NO 
reaction [108] to reduce the activation of ROS and endpoint BBB disintegration in 
CSVD. Hence, we are tempted to posit that appropriate nutritive consumptions of 
vitamin E could prove advantageous to attenuate BBB damages that underlie CSVD 
heterogenous manifestations, i.e., by halting the leukocyte-EC adhesion that can 
further degrade the BBB damages with WMHs. Biomarkers of oxidative stress can 
serve to monitor the redox imbalance in individuals with WMHs while exploring 
the putative therapeutic avenue with targeted dietary supplements as neuroprotec-
tive potentials against CSVD onset and/or disease manifestations. As such, the 
vitamin E neuroprotective merits could prevent a comprising reduction of cBF in 
cerebral ischemia in numerous CSVD manifestations, be it silent or symptomatic, 
from the ROS-centric targeting (Figure 6).
5. Challenge and future direction
Although data on therapeutic regimes had shown promising increased plasma 
levels of antioxidants, whether this translates to increased levels in the vasculature 
remains unknown. Even if sufficient levels of antioxidants were achieved in vascu-
lar cells, the antioxidants might in fact exert prooxidant effects as a result of their 
conversion to radical species following their reactions with superoxide [114, 115]. 
Either way, a single approach of conventional antioxidant supplementation would 
be suboptimal in combating oxidative stress in CSVD [108].
Corroboratively, with multiple studies having successfully linked the potential 
therapeutic and neuroprotective potentials of vitamin E in vascular health domains, 
a multicenter and adequately powered clinical trial is much needed for CSVD. Such 
data would further strengthen the nutritive value of vitamin E for CSVD neuropro-
tective supplements. In addition, opportunities exist to examine the connectivity of 
white matter tracts to exhibit vitamin E role in protection of small vessel collateral 
circulation as well as an increased expression of proarteriogenic (new blood vessel 
formation) genes in future research.
6. Conclusion
CSVD, as the commonest neurological condition as we age, could benefit from 
the potency of vitamin E antioxidant neuroprotective potentials through oxida-
tive stress and BBB integrity modulation. This chapter converges contemporary 
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